The U.S. Food and Drug Administration (FDA) first approved Lilly's
arthritis drug, baricitinib, in combination with Gilead Sciences'
remdesivir, to treat COVID-19 patients. The FDA last month expanded
the drug's authorization for lone use or with remdesivir.
Latest data from 101 patients in Lilly/Incyte's study shows patients
put on ventilators, who received baricitinib plus standard of care
were 46% less likely to die, compared with patients who received
placebo plus standard of care.
[to top of second column] |
Lilly said the new data from
the study will be shared with regulatory
authorities in the United States, European Union
and other geographies.
(Reporting by Manojna Maddipatla in Bengaluru;
Editing by Shounak Dasgupta)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |